Research

AI predicts blood clot risk in hospitalized children: VUMC study

An artificial intelligence tool developed at Vanderbilt accurately identified pediatric patients at high risk for blood clots in a clinical trial, with no difference in outcomes compared to a control group.

VUMC scientists record powerful signal in the brain’s white matter

Vanderbilt researchers report that when people who are having their brains scanned by fMRI perform a task, like wiggling their fingers, certain signals increase in white matter throughout the brain, which has long been thought to play a lesser role the more the brain’s more energetic gray matter.

Study tracks clinical team engagement with health records by patient race/ethnicity

A review of electronic health record user access logs found that EHRs of adult inpatients from minority racial and ethnic populations on average received lower engagement from health care teams than the records of white adult inpatients.

x-ray of stomach

Study validates pyrvinium as treatment to prevent stomach cancer

A Vanderbilt study found that a drug that has been used for decades for intestinal pinworms, can be repurposed as a preventative treatment for stomach cancer.

VUMC’s new automated biobanking system can store as many as 10 million biospecimens.

Research fellowship for genetic counselors established at Vanderbilt

Vanderbilt University School of Medicine has received a grant to establish a research fellowship for genetic counselors that will prepare them to contribute more fully to the advancement of personalized medicine.

Sharon Kantanie, center, participated in the study of a drug that reduced soft-tissue flare-ups and the prevented new areas of abnormal bone formation. With her are, from left, Emily Shardelow, clinical/translational research coordinator; Sharon’s parents, Mary and Stan Kantanie; Margo Black, MSN, manager of research projects for Metabolic Bone Disorders; and Kathryn Dahir, MD, professor of Endocrinology and Diabetes. (photo by Erin O. Smith)

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.

1 18 19 20 21 22 126